The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis
Open accessAbstract
Introduction: Eculizumab is effective and well tolerated in patients with antiacetylcholine receptor antibody‐positive refractory generalized myasthenia gravis (gMG; REGAIN; NCT01997229). We report an interim analysis of an open‐label extension of REGAIN, evaluating eculizumab's long‐term safety and efficacy. Methods: Eculizumab (1,200 mg every 2 weeks for 22.7 months [median]) was administered to 117 patients. Results: The safety profile of eculizumab was consistent with REGAIN; no cases of meningococcal infection were reported during the interim analysis period. Myasthenia gravis exacerbation rate was reduced by 75% from the year before REGAIN (P < 0.0001). Improvements with eculizumab in activities of daily living, muscle strength, functional ability, and quality of life in REGAIN were maintained through 3 years; 56% of patients achieved minimal manifestations or pharmacological remission. Patients who had received placebo during REGAIN experienced rapid and sustained improvements during open‐label eculizumab (P < 0.0001). Discussion: These findings provide evidence for the long‐term safety and sustained efficacy of eculizumab for refractory gMG. Muscle Nerve 2019
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myasthenia gravis: Recommendations for clinical research standards
Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America, Jaretzki, A., Barohn, R. J., Ernstoff, R. M., Kaminski, H. J., Keesey, J. C., Penn, A. S., & Sanders, D. B. (2000) · Neurology · doi:10.1212/wnl.55.1.16 · Cited by 1,651
Self-citationThe Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Hillmen, P., Young, N. S., Schubert, J., Brodsky, R. A., Socié, G., Muus, P., Röth, A., Szer, J., Elebute, M. O., Nakamura, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061648 · Cited by 1,303
International consensus guidance for management of myasthenia gravis: Executive summary
Sanders, D. B., Wolfe, G. I., Benatar, M., Evoli, A., Gilhus, N. E., Illa, I., Kuntz, N., Massey, J. M., Melms, A., Murai, H., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002790 · Cited by 1,212
Self-citationLINDSTROM, J. M., SEYBOLD, M. E., LENNON, V. A., WHITTINGHAM, S., & DUANE, D. D. (1976) · Neurology · doi:10.1212/wnl.26.11.1054 · Cited by 1,186
Howard, J. F., Utsugisawa, K., Benatar, M., Murai, H., Barohn, R. J., Illa, I., Jacob, S., Vissing, J., Burns, T. M., Kissel, J. T., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30369-1 · Cited by 845
Self-citationRother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1344 · Cited by 778 · cited 2×
“Inhibition of terminal complement activity with eculizumab is a biologically rational approach to prevent damage at the neuromuscular junction in patients with AChR refractory gMG.(22) Eculizumab has been reported to produce rapid and clinically meaningful improvements in activities of daily living, muscle strength, f…”
BackgroundMyasthenia gravis: past, present, and future
Conti-Fine, B. M., Milani, M., & Kaminski, H. J. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29894 · Cited by 691
Myasthenia gravis: recommendations for clinical research standards
Jaretzki, A., Barohn, R. J., Ernstoff, R. M., Kaminski, H. J., Keesey, J. C., Penn, A. S., & Sanders, D. B. (2000) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(00)01595-2 · Cited by 648
Self-citationMyasthenia gravis activities of daily living profile
Wolfe, G. I., Herbelin, L., Nations, S. P., Foster, B., Bryan, W. W., & Barohn, R. J. (1999) · Neurology · doi:10.1212/wnl.52.7.1487 · Cited by 572
Self-citationUse of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies
on behalf of the French Study Group for aHUS/C3G, Zuber, J., Fakhouri, F., Roumenina, L. T., Loirat, C., & Frémeaux-Bacchi, V. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.214 · Cited by 496
Vincent, A., & Newsom-Davis, J. (1985) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.48.12.1246 · Cited by 471
Reliability Testing of the Quantitative Myasthenia Gravis Scorea
BAROHN, R. J., McINTIRE, D., HERBELIN, L., WOLFE, G. I., NATIONS, S., & BRYAN, W. W. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb11015.x · Cited by 417
Self-citationMcNamara, L. A., Topaz, N., Wang, X., Hariri, S., Fox, L., & MacNeil, J. R. (2017) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6627e1 · Cited by 349
LINDSTROM, J. M., SEYBOLD, M. E., LENNON, V. A., WHITTINGHAM, S., & DUANE, D. D. (1998) · Neurology · doi:10.1212/wnl.51.4.933-a · Cited by 343
The MG Composite: A valid and reliable outcome measure for myasthenia gravis
Burns, T. M., Conaway, M. R., & Sanders, D. B. (2010) · Neurology · doi:10.1212/wnl.0b013e3181dc1b1e · Cited by 289
Self-citationMyasthenia gravis: the role of complement at the neuromuscular junction
Howard, J. F. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13522 · Cited by 213
Self-citationGajdos, P. (2005) · Archives of Neurology · doi:10.1001/archneur.62.11.1689 · Cited by 182
MG‐ADL: Still a relevant outcome measure
Muppidi, S., Wolfe, G. I., Conaway, M., Burns, T. M., & and the MG COMPOSITE AND MG‐QOL15 STUDY GROUP (2011) · Muscle & Nerve · doi:10.1002/mus.22140 · Cited by 173
Self-citationTreatment-Refractory Myasthenia Gravis
Silvestri, N. J., & Wolfe, G. I. (2014) · Journal of Clinical Neuromuscular Disease · doi:10.1097/cnd.0000000000000034 · Cited by 151
Clinical characteristics of refractory myasthenia gravis patients.
Suh, J., Goldstein, J. M., & Nowak, R. J. (2013) · PubMed · Cited by 143
Self-citationBiesecker, G., & Gomez, C. M. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.142.8.2654 · Cited by 119
C5 gene influences the development of murine myasthenia gravis.
Christadoss, P. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.140.8.2589 · Cited by 112
Minimal clinically important difference in myasthenia gravis: Outcomes from a randomized trial
Katzberg, H. D., Barnett, C., Merkies, I. S. J., & Bril, V. (2013) · Muscle & Nerve · doi:10.1002/mus.23988 · Cited by 108
McNamara, L. A., Topaz, N., Wang, X., Hariri, S., Fox, L. M., & MacNeil, J. R. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14426 · Cited by 103
Construct and concurrent validation of the MG‐QOL15 in the practice setting
Burns, T. M., Grouse, C. K., Conaway, M. R., et al. (2009) · Muscle & Nerve · doi:10.1002/mus.21609 · Cited by 91
Self-citationAbsence of IFN-γ or IL-12 Has Different Effects on Experimental Myasthenia Gravis in C57BL/6 Mice
Karachunski, P. I., Ostlie, N. S., Monfardini, C., & Conti‐Fine, B. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.10.5236 · Cited by 86
Burden of illness in patients with treatment refractory myasthenia gravis
Engel-Nitz, N. M., Boscoe, A. N., Wolbeck, R., Johnson, J., & Silvestri, N. J. (2018) · Muscle & Nerve · doi:10.1002/mus.26114 · Cited by 65
Targeting therapy to the neuromuscular junction: Proof of concept
Kusner, L. L., Satija, N., Cheng, G., & Kaminski, H. J. (2013) · Muscle & Nerve · doi:10.1002/mus.24057 · Cited by 38
Buzzard, K. A., Meyer, N. J., Hardy, T. A., Riminton, S., & Reddel, S. (2014) · Muscle & Nerve · doi:10.1002/mus.24536 · Cited by 38
Cited by
International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update
Narayanaswami, P., Sanders, D. B., Wolfe, G., Benatar, M., Cea, G., Evoli, A., Gilhus, N. E., Illa, I., Kuntz, N. L., Massey, J., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011124 · Cited by 813
Self-citationComplement in neurological disorders and emerging complement-targeted therapeutics
Dalakas, M. C., Alexopoulos, H., & Spaeth, P. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0400-0 · Cited by 363
Metadata
- Authors
- Muppidi, S., Utsugisawa, K., Benatar, M., Murai, H., Barohn, R. J., Illa, I., Jacob, S., Vissing, J., Burns, T. M., Kissel, J. T., Nowak, R. J., Andersen, H., Casasnovas, C., de Bleecker, J. L., Vu, T. H., Mantegazza, R., O'Brien, F. L., Wang, J. J., Fujita, K. P., Howard, J. F., & for the Regain Study Group
- Venue
- Muscle & Nerve
- Publisher
- Wiley
- Published
- 2019-03-08
- Volume
- 60
- Issue
- 1
- Pages
- 14-24
- ISSN
- 0148-639X (ISSN-L)
- 1097-4598
- OpenAlex
- W2912901461
- Cited by
- 262
- References
- 29
- FWCI
- 17.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.